Invest in the Future of AI-Powered Precision Health
RobGenes Holdings is a multi-vertical global ecosystem where molecular data becomes clinical intelligence, personalized intervention, and recurring international revenue.
RobGenes Holdings is not selling one test.
It is building a precision-health operating system.
Most companies sell isolated tests, supplements or software. RobGenes connects them into a unified ecosystem where each patient, physician, clinic, laboratory, and country representative increases the value of the platform.
Founded in 2024. Already $100K/month in revenue, 3,000+ patients, anchor hospitals on board.
RobGenes is not a pre-revenue science project. The platform is live across the UAE and Saudi Arabia, generating recurring income through enterprise contracts with leading hospital groups and clinics — and growing month over month.
Real contracts with leading institutions in Dubai and Saudi Arabia validate clinical-grade quality and de-risk go-to-market: distribution channels are already open.
Eight verticals. One holding company.
AI Genomics Platform
Central AI engine for clinical interpretation.
Methylation Intelligence
CpG-level epigenetic insight reports.
Genetic Supplements
Genotype-guided personalized formulas.
RobAge — Biological Age
Longevity & biomarker tracking.
Pharmacogenetics
Medication response interpretation.
Microbiome Intelligence
Gut + immune + metabolic insight.
Physician Academy
Global education & certification.
Global Licensing Network
Country master licensees.
Enter the Investor Room. Review the data room. Discuss participation.
Detailed terms, valuation models and offering documents are restricted to eligible, accredited, qualified or professional investors depending on jurisdiction.